Activation of p42/p44 mitogen-activated protein kinase by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2alpha in hepatocytes is sustained, and like the effect of epidermal growth factor, mediated through pertussis toxin-sensitive mechanisms.
Several agents that act through G-protein-coupled receptors and also stimulate phosphoinositide-specific phospholipase C (PI-PLC), including angiotensin II, vasopressin, norepinephrine, and prostaglandin (PG) F2alpha, activated the ERK1 (p44mapk) and ERK2 (p42mapk) members of the mitogen-activated protein (MAP) kinase family in primary cultures of rat hepatocytes, measured as phosphorylation of myelin basic protein (MBP) by a partially purified enzyme, immunoblotting, and in-gel assays. All these agonists induced a peak activation (two to threefold increase in MBP-phosphorylation) at 3-5 min, followed by a brief decrease, and then a sustained elevation or a second increase of the MAP kinase activity that lasted for several hours. Although all the above agents also stimulated PI-PLC, implicating a Gq-dependent pathway, the elevations of the concentration of inositol (1,4,5)-trisphosphate did not correlate well with the MAP kinase activity. Furthermore, pretreatment of the cells with pertussis toxin markedly reduced the MAP kinase activation by angiotensin II, vasopressin, norepinephrine, or PGF2alpha. In addition, hepatocytes pretreated with pertussis toxin showed a diminished MAP kinase response to epidermal growth factor (EGF). The results indicate that agonists acting via G-protein-coupled receptors have the ability to induce sustained activation of MAP kinase in hepatocytes, and suggest that Gi-dependent mechanisms are required for full activation of the MAP kinase signal transduction pathway by G-protein-coupled receptors as well as the EGF receptor.
Melien
O
O
Department of Pharmacology, Faculty of Medicine, University of Oslo, Blindern, Norway.
Thoresen
G H
GH
Sandnes
D
D
Ostby
E
E
Christoffersen
T
T
D000818:Animals; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D015237:Dinoprost / Q000494:pharmacology*; D004789:Enzyme Activation; D004815:Epidermal Growth Factor / Q000494:pharmacology; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000502:physiology*; D015544:Inositol 1,4,5-Trisphosphate / Q000032:analysis; D008099:Liver / Q000166:cytology / Q000201:enzymology*; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D009479:Neuropeptides / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology*; D037342:Pertussis Toxin; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D009479:Neuropeptides; D010566:Virulence Factors, Bordetella; D004815:Epidermal Growth Factor; D015544:Inositol 1,4,5-Trisphosphate; D004247:DNA; D015237:Dinoprost; D037342:Pertussis Toxin; D019950:Mitogen-Activated Protein Kinase 1; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D009638:Norepinephrine